Amphotericin B-Deoxycholate is as Effective and Safe as the Costly Amphotericin B Colloidal Dispersion in the Treatment of Paediatric Invasive Fungal Infections

Authors

  • Sarinah Tamring Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • Tey Ie Lane Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • Hani Syazwani Mohd Shah Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • Harikrishnan Shanmuganathan Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • Tzar Mohd Nizam Khaithir Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • Ahmad Nazrun Shuid Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • Boekhtiar Borhanuddin Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • Isa Naina Mohamed Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

DOI:

https://doi.org/10.6000/1927-5951.2014.04.04.1

Keywords:

 Amphotericin B, Amphotericin B colloidal dispersion, Amphotericin B deoxycholate, Liposomal Amphotericin B, Paediatrics Invasive Fungal Infections (IFI), Antifungals.

Abstract

Amphotericin B deoxycholate (AmBD) and amphotericin B colloidal dispersion (AmBCD) are the two most commonly used antifungals for invasive fungal infections (IFI) among paediatric patients. The objective of this pilot study was to compare the efficacy, adverse effects and cost-effectiveness between AmBD and AmBCD in the treatment of IFI among paediatric patients admitted at Universiti Kebangsaan Malaysia Medical Centre (UKMMC).
Methods: Secondary data analysis of the medical records of all paediatric patients with IFI was obtained and data extraction was performed for patients admitted between July 1, 2006 and June 30, 2011. Efficacy of treatment was determined and reports of adverse effects were noted.
Results: Between July 1, 2006 and June 30, 2011, thirty-five patients received AmBD-only treatment and five patients received AmBCD-only treatment. Twenty-four patients were males and the mean age was 7.18 (SD 4.59) years. On average, the AmBCD treatment course was significantly more expensive than AmBD (p<0.01). Patients on AmBD had more adverse effects compared to those on AmBCD. However, there was no significant difference in severe adverse events between these groups. There was no significant difference in efficacy between these groups, in terms of IFI resolution or treatment duration.
Conclusion: These findings imply that the use of AmBD instead of AmBCD in IFI treatment among paediatric patients is justified, given its cost-effectiveness, as there was no significant difference in the efficacy or in the incidence of severe adverse effects between these two treatments.

References

Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 12: 101-111. http://dx.doi.org/10.1016/0002-9343(82)90594-0

Zaoutis TE, Argos J, Chu J, Berlin JA, Walsh TJ, Feudner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239. http://dx.doi.org/10.1086/496922

Rodriguez-Nunez A. Incidence and mortality of proven invasive Candida infections in paediatric intensive care patients. Infection Control and Hospital Epidemiology 2011; 22: 477-478. http://dx.doi.org/10.1086/503410

Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive Aspergillus infections in a paediatric hospital: a ten-year review. Pediatr Infect Dis J 1993; 12: 673-682. http://dx.doi.org/10.1097/00006454-199308000-00009

Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999; 29: 1210-1219. http://dx.doi.org/10.1086/313445

Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy and influences on mortality in hospitalized adult and paediatric patients. Clin Infect Dis 2003; 37: 634-643. http://dx.doi.org/10.1086/376906

EORTC International Antimicrobial Therapy Co-operative Group. Empiric antifungal therapy in febrile granulocytopenia. Am J Med 1989; 86: 668-672. http://dx.doi.org/10.1016/0002-9343(89)90441-5

Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Invest Dermatol 1995; 20: 755-761.

Kleinberg M. What is the current and future status of conventional amphotericin B? Int J of Antimicrob Agents 2006; 27S: S12-S16. http://dx.doi.org/10.1016/j.ijantimicag.2006.03.013

Joly V, Bolard J, Saint-Julien L, Carbon C, Yeni P. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations. Antimicrob Agents Chemother 1992; 36: 262-266. http://dx.doi.org/10.1128/AAC.36.2.262

Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of Amphotericin B: Clinical Efficacy and Toxicities. Clin Infect Dis 1998; 27: 603-618. http://dx.doi.org/10.1086/514704

Allende MC, Lee JW, Francis P, Garrett K, Dollenberg H, Berenguer J, Lyman CA, Pizzo PA, Walsh TJ. Dose-depen-dent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38: 518-22. http://dx.doi.org/10.1128/AAC.38.3.518

Bowden RA, Cays M, Gooley T, Mamelok RD, Van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996; 173: 1208-15. http://dx.doi.org/10.1093/infdis/173.5.1208

Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin B colloidal dispersion for treatment of Candidemia in immunocompromised patients. Clin Infect Dis 1998; 26: 461-7. http://dx.doi.org/10.1086/516314

Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and efficacy of amphotericin B colloidal dispersion. Chemotherapy 1999; 45(suppl 1): 67-76. http://dx.doi.org/10.1159/000048472

White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, Gurwith M, Mond CD, Mamelok RD, Bowden RA. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635-42.

White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302. http://dx.doi.org/10.1086/514672

Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, Burik JAV, Laverdiere M, Safrin S, Wingard JR. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-366. http://dx.doi.org/10.1086/341401

De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 2008; 46: 1813-21. http://dx.doi.org/10.1086/588660

Pappas PG. Clinical practice guidelines for the management of Candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009; 48: 503-35. http://dx.doi.org/10.1086/596757

Katragkou A, Roilides E. Best practice in treating infants and children with proven, probable or suspected invasive fungal infections. Curr Opin Infect Dis 2011; 24: 225-229. http://dx.doi.org/10.1097/QCO.0b013e3283460e22

Rohrig B, du Prel JB, Blettner M. Types of study in medical research. Dtsch Arztebl Int 2009; 106(15): 262-8.

Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses study group and European organization for research and treatment of cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83. http://dx.doi.org/10.1086/590566

Laniado-Laborin R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol 2009; 26(4): 223-227. http://dx.doi.org/10.1016/j.riam.2009.06.003

Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212. http://dx.doi.org/10.1186/cc2872

U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER) 2009. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation.

Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of Amphotericin B Colloidal Dispersion in Children. J Pediatr Hematol Oncol 2000; 22(3): 242-246. http://dx.doi.org/10.1097/00043426-200005000-00009

Robinson RF, Nahata MC. A comparative review of conventional & lipid formulations of amphotericin B. J Clin Pharm Ther 1999; 24: 249-257. http://dx.doi.org/10.1046/j.1365-2710.1999.00220.x

Ministry of Health Malaysia’s National Cancer Registry Report. Malaysia Cancer Statistics - Data and Figure 2007.

Downloads

Published

2014-08-05

How to Cite

Sarinah Tamring, Tey Ie Lane, Hani Syazwani Mohd Shah, Harikrishnan Shanmuganathan, Tzar Mohd Nizam Khaithir, Ahmad Nazrun Shuid, Boekhtiar Borhanuddin, & Isa Naina Mohamed. (2014). Amphotericin B-Deoxycholate is as Effective and Safe as the Costly Amphotericin B Colloidal Dispersion in the Treatment of Paediatric Invasive Fungal Infections. Journal of Pharmacy and Nutrition Sciences, 4(4), 228–237. https://doi.org/10.6000/1927-5951.2014.04.04.1

Issue

Section

Articles